ChromoBlog

Recent Posts

Analyze protein interactions live in mammalian cells

Posted by Christoph Eckert on May 16, 2017 4:18:31 PM

  • Do you have GFP or RFP protein constructs and/or libraries?
  • Do you want to screen agonists or antagonists?
  • Do you want to save time and start your experiment without method set-up?

Just do it. All you need is the ChromoTek F2H Kit Basic: Transfect the bait and the prey plasmids with the Platform Reagent into the F2H cells. Image and quantify your results already at the next day.

Read More

Topics: F2H assay, PPI

ChromoTek Introduces the new F2H® Kit for Protein-Protein Interaction Analysis

Posted by Larisa Yurlova on Mar 31, 2014 5:33:00 PM

ChromoTek GmbH (Martinsried, Germany) announces the launch of a new research assay for protein-protein interaction (PPI)analysis in live mammalian cells, the Fluorescence Two-Hybrid (F2H®) Kit. This new product is the result of Chromotek's long experience with applying the F2H technology in PPI compound screening for pharmaceutical and biotech customers. The new kit format overcomes limitations of currently available methods and will fascinate biomedical scientists, who investigate protein-protein interactions (PPIs) by its ease of use.

ChromoTek’s F2H® Kit enables effortless analysis of interactions between any GFP- and RFP- tagged protein pairs in living mammalian cells by conventional fluorescence microscopy. It is a fast, simple and quantitative way to characterize PPIs in intracellular environment, screen for PPI inhibitors and evaluate their activity in real time. Unlike available complementation assays, such as split-YFP, F2H® is a fully reversible assay and therefore better suitable for testing PPI antagonists. In comparison to FRET assays, the ingeniously simple optical read-out of F2H® does not require sophisticated equipment, making it much more affordable and at the same time robust and reliable.

Read More

Topics: F2H assay, HCA, protein-protein interaction, p53/Mdm2, p53/Mdm4, PPI, PPI inhibitor, cellular PPI assay, PPI dynamics

ChromoTek and NMI TT ally to start a new chapter in HCA

Posted by Katrin Schmidthals on Mar 24, 2014 6:01:00 PM

ChromoTek GmbH (Martinsried, Germany) and NMI Technology Transfer GmbH (Reutlingen, Germany) have joined forces to advance ChromoTek ́s proprietary Chromobody® technology in new cellular models. 

Chromobodies® are new intracellular functional antibodies visualising dynamic changes of target proteins in live cells. With the help of NMI`s outstanding lentiviral transduction technology, Chromobodies® will be introduced into difficult-to-transfect cell lines such as primary cells. The cooperation will establish innovative cell lines available for phenotypic screening, target validation and high content analysis (HCA). The unique combination of Chromobody® nanoprobes and a comprehensive collection of disease-relevant cellular test systems will lift preclinical compound screening and pathway analysis in the early drug discovery process to a new level of performance.

Read More

Topics: Chromobodies, Nano-Traps, Nano-Booster, F2H assay, GFP-Trap, Nano-Trap, high content analysis, HCA, Chromobody

Protein-protein interactions: see them, screen then, publish!

Posted by Larisa Yurlova on Mar 20, 2014 1:40:00 PM

Yes! Our latest paper reporting on screening for protein-protein interaction inhibitors with F2H is now online: http://www.ncbi.nlm.nih.gov/pubmed/24476585.

Read More

Topics: F2H assay, p53/Mdm2, p53/Mdm4, protein-protein interaction, PPI, PPI inhibitor, cellular PPI assay, PPI dynamics

Meet us at #SfN13

Posted by Joerg Katzenberger on Nov 9, 2013 8:45:00 PM

Read More

Topics: Chromobodies, Roadshow, USA, Nano-Traps, Nano-Booster, F2H assay, protein-protein interaction, GFP-Trap, Nano-Trap

We present two posters at #MipTec2013 in Basel

Posted by Joerg Katzenberger on Sep 23, 2013 9:56:00 PM

 
  • Intracellular Fluorescent Alpaca Antibodies (Chromobodies):
    Non-invasive Biomarkers for High-Content Analysis in Mammalian Cells
  • Development of Comparative, Cell-based, Reversible p53:Mdm2 and p53:Mdm4 High-Content Fluorescent Two-Hybrid (F2H) Assays for Drug Screening
Read More

Topics: Chromobodies, F2H assay, p53/Mdm2, p53/Mdm4, protein-protein interaction, PPI, PPI inhibitor, cellular PPI assay, PPI dynamics

ChromoTek's Chromobody® Technology for HC drug profiling licensed to Bayer

Posted by Katrin Schmidthals on Mar 18, 2013 11:21:00 AM

ChromoTek GmbH (Munich, Germany) has announced today the signing of a license agreement granting Bayer Pharma AG (Bayer) the right to use ChromoTek's proprietary Cell Cycle Chromobody® Technology for drug profiling by High Content Analysis. Under the terms of the agreement, Bayer will apply Chromobody® technology for real time monitoring of cell cycle progression in drug discovery. Financial terms of the agreement were not disclosed. This agreement follows a collaboration in which ChromoTek provided custom cell line development.

ChromoTek's Chromobody® Technology is a patented, universal live cell imaging technology for high content analysis. Chromobodies are single domain antibodies that have been genetically fused to fluorescent proteins to serve as functional nanoprobes in living cells. The Chromobody® technology allows for the first time to trace endogenous intracellular antigens and to visualize dynamic changes of these targets within living cells. Currently available Chromobodies trace important cellular processes like cell cycle, apoptosis, DNA damage and repair or allow cytoskeletal analysis. The Cell Cycle Chromobody® cell line licensed by Bayer traces the complete cell cycle in real time in live cells in a non-invasive manner while providing full flexibility to multiplex with other procedures.

Dr. Kourosh Zolghadr, Head of R&D at ChromoTek comments: "We are pleased to offer our customers efficient tools for achieving more detailed and physiologically relevant information on the effects of drug candidates on cell cycle progression."

About ChromoTek

ChromoTek products set new benchmarks for cellular research. Established in 2008 as a spin-off from Munich’s Ludwig Maximilian University and located in Martinsried, Germany’s leading biotech cluster, ChromoTek develops and markets Chromobody® based live cell assays for drug screening and target validation. Other products include immunological and bioimaging reagents such as the GFP- Trap® for the rapid pull-down of GFP fusion proteins, GFP and RFP-Booster to amplify fluorescence signals of GFP or RFP fusion proteins. ChromoTek’s newly developed fluorescence based protein protein interaction assay called Fluorescent-2-Hybrid (F2H® assay) is available as a development service. More than 2.800 customers from all over the world trust in ChromoTek products.

Download Press release

Posted by Katrin on Mar 18, 2013

Read More

Topics: Chromobodies, Nano-Traps, Nano-Booster, F2H assay, GFP-Trap, Nano-Trap, high content analysis, HCA, Chromobody cell line, Cell Cycle Chromobody

Biomolecular movies: ChromoTek introduces Chromobody® plasmids

Posted by Katrin Schmidthals on Mar 11, 2013 10:09:00 AM

ChromoTek GmbH (Munich, Germany) offers nanobody based real time assays to visualize and measure the action of candidate drugs or other substances of interest on important regulatory processes in living cells. Presently, four Chromobody® plasmids are available for analyzing the cell cycle, apoptosis, DNA methylation and cytoskeleton dynamics.

Read More

Topics: Chromobodies, Nano-Traps, Nano-Booster, F2H assay, GFP-Trap, Nano-Trap, high content analysis, HCA, Chromobody, Chromobody plasmid

ChromoTek and Cell Culture Service Enter into a Partnership to Market Chromobody® Cell Lines

Posted by Katrin Schmidthals on Mar 16, 2012 9:21:00 AM

ChromoTek GmbH (Munich, Germany) and Cell Culture Service GmbH (Hamburg, Germany) have entered into a service, distribution and co-marketing partnership. 

Under the agreement, Cell Culture Service will provide Chromobody® cells for direct use in live cell assays. These express fluorescently labeled intracellular antibodies allowing real time monitoring of endogenous intracellular proteins. Biotechnology or pharmaceutical companies will be offered Chromobody® cell lines or transient bulk transfections of own cell lines in assay ready formats to enhance their drug discovery and high throughput screening capabilities.

Chromobodies are single domain antibodies that are genetically fused to fluorescent proteins to serve as functional nanoprobes in living cells. The Chromobody® technology allows for the first time to trace endogenous intracellular antigens and to visualize dynamic changes of these targets in living cells. Currently available cell lines allow the high content analysis of the full cell cycle and real time monitoring of apoptotic events. Small molecule libraries can be screened for desired or adverse effects on a cellular level in multiwell formats. "The combination of dynamic live cell analysis and high content read out closes a gap in drug discovery and I am delighted to facilitate the use of this novel technology for my customers", states Dr. Oliver Wehmeier, Managing Director and President of Cell Culture Service. "We are impressed with CCS’ capabilities to manufacture any type of cell based reagent in any type of cell and assay format for Chromobody® customers " says Dr. Marion Jung, Managing Director of ChromoTek.

Customers who have licensed a cell line from ChromoTek can order these cells from CCS directly. Customers who would like to get access to ChromoTek’s technology for the first time can license the cell line or order assay-ready frozen instant cells via ChromoTek or via CCS.

About CCS Cell Culture Service (now a member of the Evotec group)

For more than eleven years, CCS has been supporting research departments of pharmaceutical and biotechnology companies in their efforts to discover new drug entities by supplying them with custom made functionally validated cell based reagents.
CCS is one of the leading suppliers of recombinant cell lines, assay-ready frozen cells, qualified membranes, and proteins for high-throughput screening. Major pharmaceutical companies all over Europe and the USA now rely on the custom products and services of CCS.

About ChromoTek

ChromoTek products set new benchmarks for cellular research. The company was established in 2008 as a spin-off from Munich’s Ludwig Maximilian University and is located in Martinsried, Germany’s leading biotech cluster. ChromoTek develops and markets immunological and bioimaging reagents and cellular assays for biomedical research and drug discovery. These include the GFP-Trap® for the rapid pull-down of GFP fusion proteins, GFP and RFP Booster for intensifying the fluorescence signal of GFP or RFP fusion proteins, Chromobody® based live cell assays for screening and validation and a fluorescence based protein-protein interaction assay called Fluorescent-2-Hybrid (F2H®). More than 1.900 customers from all over the world trust in ChromoTek products.

Download Press release

Posted by Katrin on Mar 16, 2012 

Read More

Topics: Chromobodies, Nano-Traps, Nano-Booster, F2H assay, GFP-Trap, Nano-Trap, high content analysis, HCA, Chromobody

ChromoTek showing a poster about its latest developments:

Posted by Katrin Schmidthals on Jan 4, 2012 2:10:00 AM


High Content Analysis Meeting 2012  in  San Francisco. January 10-13, 2012 at 
The Fairmont Hotel
Read More

Topics: Chromobodies, USA, Nano-Booster, F2H assay, protein-protein interaction, PPI, GFP-Trap, Nano-Trap

ChromoBlog

Posted by

Subscribe to Email Updates

Recent Posts

Posts by Topic

see all